Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.

European journal of clinical pharmacology - 1 Oct 2007

Kubota Ryuji, Ohno Masako, Hasunuma Tomoko, Iijima Hajime, Azuma Junichi

Abstract excerpt

OBJECTIVE: Genetic polymorphisms of arylamine N-acetyltransferase 2 (NAT2) result in large interindividual differences in the plasma concentration of isoniazid (INH). We hypothesized that the internationally recommended dosage should be increased for patients with two active NAT2 alleles (RA type) in order to achieve appropriate antituberculous efficiency; however, the pharmacokinetic effects of the dose increase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antitubercular Agents

Share to Area Under Curve

Share to Arylamine N-Acetyltransferase

Share to Isoniazid

Share to Polymorphism, Genetic

Share to Reference Values

Source

Identifiers

PMID: 17665185
DOI: 10.1007/s00228-007-0333-1

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.PMID 17665185Read ↗

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

A study of N-acetyltransferase 2 gene polymorphisms in the Indian population and its relationship with serum isoniazid concentrations in a cohort of tuberculosis patients.Semantic proximity Read ↗

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.Semantic proximity Read ↗

Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects.Semantic proximity Read ↗

A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.Semantic proximity Read ↗

N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.Semantic proximity Read ↗

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.